Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095199 · ClinicalTrials.gov registry record · Phase 3
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 939
- Enrollment target
NCT00095199 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 939 participants.
The verdict
NCT00095199, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 939 participants
- Enrollment target
Study Summary
This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \& Pemetrexed or Pemetrexed alone; Cetuximab \& Docetaxel or Docetaxel alone).
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- BIOLOGICAL Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 939 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095199
The ClinicalTrials.gov registry entry for NCT00095199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 939 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00095199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095199 about?
NCT00095199 is a clinical study titled "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer". This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice...
What is the current status of trial NCT00095199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 939 participants. The study started on 2005-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00095199?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), Cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00095199?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.